388 related articles for article (PubMed ID: 28438386)
1. Catabolism of antibody drug conjugates and characterization methods.
Shadid M; Bowlin S; Bolleddula J
Bioorg Med Chem; 2017 Jun; 25(12):2933-2945. PubMed ID: 28438386
[TBL] [Abstract][Full Text] [Related]
2. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
[TBL] [Abstract][Full Text] [Related]
3. Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates.
Sauerborn M; van Dongen W
BioDrugs; 2014 Aug; 28(4):383-91. PubMed ID: 24842227
[TBL] [Abstract][Full Text] [Related]
4. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
[TBL] [Abstract][Full Text] [Related]
5. Strategies to address drug interaction potential for antibody-drug conjugates in clinical development.
Lu D; Sahasranaman S; Zhang Y; Girish S
Bioanalysis; 2013 May; 5(9):1115-30. PubMed ID: 23641700
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of bioconjugate therapeutics: why, when, and how?
Liu H; Bolleddula J; Nichols A; Tang L; Zhao Z; Prakash C
Drug Metab Rev; 2020 Feb; 52(1):66-124. PubMed ID: 32045530
[TBL] [Abstract][Full Text] [Related]
7. An enzymatic deconjugation method for the analysis of small molecule active drugs on antibody-drug conjugates.
Li Y; Gu C; Gruenhagen J; Yehl P; Chetwyn NP; Medley CD
MAbs; 2016; 8(4):698-705. PubMed ID: 26891281
[TBL] [Abstract][Full Text] [Related]
8. Analysis of small molecule antibody-drug conjugate catabolites in rat liver and tumor tissue by liquid extraction surface analysis micro-capillary liquid chromatography/tandem mass spectrometry.
Lanshoeft C; Stutz G; Elbast W; Wolf T; Walles M; Stoeckli M; Picard F; Kretz O
Rapid Commun Mass Spectrom; 2016 Apr; 30(7):823-32. PubMed ID: 26969923
[TBL] [Abstract][Full Text] [Related]
9. Practical approaches for overcoming challenges in heightened characterization of antibody-drug conjugates with new methodologies and ultrahigh-resolution mass spectrometry.
Friese OV; Smith JN; Brown PW; Rouse JC
MAbs; 2018 Apr; 10(3):335-345. PubMed ID: 29393747
[TBL] [Abstract][Full Text] [Related]
10. Universal Affinity Capture Liquid Chromatography-Mass Spectrometry Assay for Evaluation of Biotransformation of Site-Specific Antibody Drug Conjugates in Preclinical Studies.
Kotapati S; Passmore D; Yamazoe S; Sanku RKK; Cong Q; Poudel YB; Chowdari NS; Gangwar S; Rao C; Rangan VS; Cardarelli PM; Deshpande S; Strop P; Dollinger G; Rajpal A
Anal Chem; 2020 Jan; 92(2):2065-2073. PubMed ID: 31860282
[TBL] [Abstract][Full Text] [Related]
11. A new anti-human Fc method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in serum from pre-clinical species.
Excoffier M; Janin-Bussat MC; Beau-Larvor C; Troncy L; Corvaia N; Beck A; Klinguer-Hamour C
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():149-154. PubMed ID: 27267073
[TBL] [Abstract][Full Text] [Related]
12. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
13. Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells.
Salomon PL; Singh R
Mol Pharm; 2015 Jun; 12(6):1752-61. PubMed ID: 25738394
[TBL] [Abstract][Full Text] [Related]
14. Antibody-drug conjugates for cancer.
Chau CH; Steeg PS; Figg WD
Lancet; 2019 Aug; 394(10200):793-804. PubMed ID: 31478503
[TBL] [Abstract][Full Text] [Related]
15. Cell killing by antibody-drug conjugates.
Kovtun YV; Goldmacher VS
Cancer Lett; 2007 Oct; 255(2):232-40. PubMed ID: 17553616
[TBL] [Abstract][Full Text] [Related]
16. Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics.
Sukumaran S; Zhang C; Leipold DD; Saad OM; Xu K; Gadkar K; Samineni D; Wang B; Milojic-Blair M; Carrasco-Triguero M; Rubinfeld B; Fielder P; Lin K; Ramanujan S
AAPS J; 2017 Jan; 19(1):130-140. PubMed ID: 27679517
[TBL] [Abstract][Full Text] [Related]
17. A Brief Introduction to Antibody-Drug Conjugates for Toxicologic Pathologists.
Mecklenburg L
Toxicol Pathol; 2018 Oct; 46(7):746-752. PubMed ID: 30295169
[TBL] [Abstract][Full Text] [Related]
18. Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates.
Saad OM; Shen BQ; Xu K; Khojasteh SC; Girish S; Kaur S
Bioanalysis; 2015; 7(13):1583-604. PubMed ID: 26226309
[TBL] [Abstract][Full Text] [Related]
19. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
Tsuchikama K; An Z
Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
[TBL] [Abstract][Full Text] [Related]
20. Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines.
Papachristos A; Pippa N; Demetzos C; Sivolapenko G
Drug Deliv; 2016 Jun; 23(5):1662-6. PubMed ID: 25625494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
